2.52

1.81% 0.04

Black Diamond Therapeutics Inc (BDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Black Diamond Therapeutics Inc stock is traded at $2.52, with a volume of 1.07M. It is up +1.81% in the last 24 hours and up +14.77% over the past month. Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Previous Close:

$2.48

Open:

$2.48

24h Volume:

1.07M

Relative Volume:

0.32

Market Cap:

$139.88M

Revenue:

Net Income/Loss:

$-82.44M

P/E Ratio:

-1.3404

EPS:

-1.88

Net Cash Flow:

$-66.75M

1W Performance:

+1.41%

1M Performance:

+14.77%

6M Performance:

+17.99%

1Y Performance:

-46.28%

1-Day Range:

$2.435

$2.62

1-Week Range:

$2.34

$2.71

52-Week Range:

$1.195

$6.75

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Name

Black Diamond Therapeutics Inc

Sector

Healthcare (1175)

Industry

Biotechnology (661)

Phone

617-417-5868

Address

ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

BDTX's Discussions on Twitter

Compare BDTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDTX Black Diamond Therapeutics Inc	2.51	139.88M	0	-82.44M	-66.75M	-1.88
VRTX Vertex Pharmaceuticals Inc	451.91	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	537.25	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	321.13	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	547.08	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	243.26	28.51B	3.81B	-644.79M	-669.77M	-6.24

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-24	Initiated	Raymond James	Outperform
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold
Jan-07-21	Initiated	Wedbush	Outperform
Nov-24-20	Initiated	Berenberg	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	Canaccord Genuity	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	JP Morgan	Overweight
Feb-24-20	Initiated	Jefferies	Buy

View All

Black Diamond Therapeutics Inc Stock (BDTX) Latest News

Jun 16, 2025

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Holdings Boosted by Bank of America Corp DE - Defense World

Jun 16, 2025

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Rating of “Buy” from Analysts - Defense World

Jun 16, 2025

Jun 14, 2025

Black Diamond Therapeutics (NASDAQ:BDTX) Upgraded at Wall Street Zen - Defense World

Jun 14, 2025

Jun 12, 2025

Black Diamond’s 2025 Annual Stockholders Meeting Highlights - TipRanks

Jun 12, 2025

Jun 10, 2025

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside - Seeking Alpha

Jun 10, 2025

Jun 08, 2025

Wellington Management Group LLP Grows Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

Jun 08, 2025

Jun 07, 2025

Squarepoint Ops LLC Buys 72,688 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

Jun 07, 2025

Black Diamond Therapeutics (NASDAQ:BDTX) Downgraded to Hold Rating by Wall Street Zen - Defense World

Jun 07, 2025

Jun 06, 2025

Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews

Jun 06, 2025

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Acquired by Nuveen Asset Management LLC - Defense World

Jun 06, 2025

Jun 05, 2025

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Purchased by Millennium Management LLC - Defense World

Jun 05, 2025

May 30, 2025

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Acquired by Northern Trust Corp - Defense World

May 30, 2025

May 29, 2025

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewswire

May 29, 2025

17,317 Shares in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Bought by D. E. Shaw & Co. Inc. - Defense World

May 29, 2025

May 26, 2025

Black Diamond Therapeutics (NASDAQ:BDTX) & Fresh Tracks Therapeutics (NASDAQ:FRTX) Critical Comparison - Defense World

May 26, 2025

May 25, 2025

Brokerages Set Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Price Target at $14.60 - Defense World

May 25, 2025

May 24, 2025

Black Diamond Therapeutics (NASDAQ:BDTX) Raised to Buy at Wall Street Zen - Defense World

May 24, 2025

May 23, 2025

Black Diamond Therapeutics Reports Strong Q1 2025 Earnings - TipRanks

May 23, 2025

May 20, 2025

3 Promising Penny Stocks With Market Caps Under $200M - Yahoo Finance

May 20, 2025

May 19, 2025

Price T Rowe Associates Inc. MD Cuts Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

May 19, 2025

May 17, 2025

Wedbush Issues Optimistic Estimate for BDTX Earnings - Defense World

May 17, 2025

May 16, 2025

Dimensional Fund Advisors LP Has $1.42 Million Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

May 16, 2025

May 15, 2025

Raymond James Financial Inc. Makes New Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

May 15, 2025

May 14, 2025

Stifel Financial Corp Raises Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

May 14, 2025

Wells Fargo & Company MN Buys 5,932 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

May 14, 2025

May 13, 2025